Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Should Be Allowed To Schedule Foreign Inspections Based On Risk – CDER’s Woodcock

This article was originally published in PharmAsia News

Executive Summary

Potential legislation to strengthen FDA oversight of foreign drug producers should allow the agency to target facilities and products based on risk, Center for Drug Research and Evaluation Director Janet Woodcock recommended at a May 1 House Energy and Commerce Health Subcommittee hearing
Advertisement

Related Content

U.S. FDA, PDA Kick Off First Conference On Quality Systems For China’s Manufacturers, Suppliers
U.S. FDA, PDA Kick Off First Conference On Quality Systems For China’s Manufacturers, Suppliers
U.S. FDA’s Poor Performance ‘Invites Catastrophe’ – U.S. Congressional Committee On Heparin Investigation
U.S. FDA’s Poor Performance ‘Invites Catastrophe’ – U.S. Congressional Committee On Heparin Investigation
Advertisement
UsernamePublicRestriction

Register

SC068508

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel